Proactive Investors - Run By Investors For Investors

Motif Bio completes FDA submission for Iclaprim antibiotic

The AIM-listed bio-pharma company said Iclaprim had received Qualified Infectious Disease Product designation from the FDA together with Fast Track Designation
If accepted by the FDA, Iclaprim will have a review period of six months rather than ten

Motif Bio Plc (LON:MTFB) has completed a rolling submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its new antibiotic Iclaprim.

The AIM-listed bio-pharma company said Iclaprim, a targeted, Gram-positive investigational antibiotic for the treatment of acute bacterial skin and skin structure infections, had received Qualified Infectious Disease Product (QIDP) designation from the FDA together with Fast Track Designation.

WATCH: Motif Bio completes rolling submission of NDA for new antibiotic Iclaprim

The group added that upon acceptance of the filing of the NDA by the FDA, Iclaprim would receive priority review, a review period of six months instead of the standard ten months. 

If Iclaprim is approved as a new chemical entity with QIDP designation, it will be eligible for 10 years of market exclusivity in the US starting from the date of approval.

The news follows an announcement earlier this week when Motif confirmed that Iclaprim was confirmed to be better tolerated and safer than a rival drug in two recent late-stage studies.

In early-morning trading Thursday, Motif Bio shares were up 1% at 32.7p.

--Adds share price--

View full MTFB profile View Profile

Motif Bio Plc Timeline

Related Articles

scientist in lab
September 11 2018
The phase 1b trial of Silence’s lead candidate, SLN124, a treatment for a rare blood disorder, is scheduled to begin in the second half of 2019
Woman sneezing
September 27 2018
"We look forward to the exciting developments in our early pipeline planned for 2019, and we expect to continue to grow our European business while progressing towards US and German registration for our lead products," said company chairman, Peter Jensen
June 04 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering
Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use